The lung microbiome in end-stage Lymphangioleiomyomatosis

Respir Res. 2021 Oct 26;22(1):277. doi: 10.1186/s12931-021-01873-y.ABSTRACTLymphangioleiomyomatosis (LAM) is a progressive cystic lung disease with mortality driven primarily by respiratory failure. Patients with LAM frequently have respiratory infections, suggestive of a dysregulated microbiome. Here we demonstrate that end-stage LAM patients have a distinct microbiome signature compared to patients with end-stage chronic obstructive pulmonary disease.PMID:34702264 | DOI:10.1186/s12931-021-01873-y

Source: Respiratory Care - October 27, 2021 Category: Respiratory Medicine Authors: Julie Ng Gustavo Pacheco-Rodriguez Lesa Begley Yvonne J Huang Sergio Poli Mark A Perrella Ivan O Rosas Joel Moss Souheil El-Chemaly Source Type: research